ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, vol.125, no.4, pp.460-467, 2020 (SCI-Expanded)
Background: Intravenous recombinant enzyme replacement therapy (ERT) is currently available for 8 lysosomal diseases. Hypersensitivity reactions (HSRs) may be observed during this long-term treatment.